Development of a preclinical 211Rn/211At generator system for targeted alpha therapy research with 211At

This study demonstrated the feasibility of using generator-produced 211At to label monoclonal antibody (BC8, anti-human CD45) for preclinical use, following isolation from the 207Po contamination also produced by these generators (by 211Rn α-decay).

Source: Nuclear Medicine and Biology - January 28, 2017 Category: Nuclear Medicine Authors: Jason R Crawford, Hua Yang, Peter Kunz, D Scott Wilbur, Paul Schaffer, Thomas J Ruth Source Type: research